Evidence map›Paper›PMID 26437064›Full record

ArticleBone marrow transplantation2016

Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ⩾55 years with hematological malignancies.

K Miyao, M Sawa, Y Kuwatsuka, Y Ozawa, T Kato, A Kohno, H Sao, T Nishida, H Iida, K Naito and 10 more

Abstract readLetterMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

K MiyaoDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
M SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Y KuwatsukaCenter for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
Y OzawaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
T KatoDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
A KohnoDepartment of Hematology and Oncology, Konan Kosei Hospital, Konan, Japan.
H SaoDivision of Hematology, Meitetsu Hospital, Nagoya, Japan.
T NishidaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
H IidaDepartment of Hematology, Nagoya Medical Center, Nagoya, Japan.
K NaitoDepartment of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan.
H TsurumiFirst Department of Internal Medicine, Gifu University, Gifu, Japan.
H TajiDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
S MizutaDepartment of Hematology, Fujita Health University, Toyoake, Japan.
S KusumotoDepartment of Medical Oncology and Immunology, Nagoya City University, Nagoya, Japan.
K NakaseDepartment of Hematology and Oncology, Mie University, Tsu, Japan.
Y MorishitaDepartment of Hematology and Oncology, Konan Kosei Hospital, Konan, Japan.
N KawashimaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
K MiyamuraDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
M MurataDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya Blood and Marrow Transplantation Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematopoietic Stem Cell TransplantationTransplantation ConditioningAgedAged, 80 and overAllograftsDisease-Free SurvivalFemaleHematologic NeoplasmsHumansMaleMelphalanMiddle AgedRetrospective StudiesSurvival RateVidarabinefludarabineMelphalanVidarabine

Identifiers

PMID26437064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.